Our findings are consistent with those previously observed, showing that decreased Beclin-1 expression was correlated with a lower survival rate in patients with esophageal cancer, glioblastoma and colon cancers [22,24,37], and with the observation that high expression of Beclin-1 correlates with a better survival rate in non-Hodgkin lymphoma patients [36]. This evidence concerns the gene BECN1 and esophageal cancer.